Search results
Showing 3051 to 3100 of 4090 results for patient
Elamipretide for treating Barth syndrome in people of any age [ID6545]
In development Reference number: GID-TA11719 Expected publication date: TBC
Awaiting development Reference number: GID-TA11687 Expected publication date: TBC
Workplace health: long-term sickness absence and capability to work (NG146)
This guideline covers how to help people return to work after long-term sickness absence, reduce recurring sickness absence, and help prevent people moving from short-term to long-term sickness absence.
Bipolar, schizophrenia and other psychoses: cervical screening (IND85)
This indicator covers the percentage of women aged 25 or over and who have not attained the age of 65 with schizophrenia, bipolar affective disorder and other psychoses whose notes record that a cervical screening test has been performed in the preceding 5 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM20
This indicator covers the contractor establishing and maintaining a register of patients with atrial fibrillation, including patients with ‘AF resolved’. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM164
This guideline covers referral and assessment for intermediate care and how to deliver the service. Intermediate care is a multidisciplinary service that helps people to be as independent as possible. It provides support and rehabilitation to people at risk of hospital admission or who have been in hospital. It aims to ensure people transfer from hospital to the community in a timely way and to prevent unnecessary admissions to hospitals and residential care.
Autism spectrum disorder in under 19s: support and management (CG170)
This guideline covers children and young people with autism spectrum disorder (across the full range of intellectual ability) from birth until their 19th birthday. It covers the different ways that health and social care professionals can provide support, treatment and help for children and young people with autism, and their families and carers, from the early years through to their transition into young adult life.
Pimicotinib for treating tenosynovial giant cell tumours when systemic treatment is needed [ID6647]
In development Reference number: GID-TA11859 Expected publication date: TBC
Awaiting development Reference number: GID-TA11615 Expected publication date: TBC
Awaiting development Reference number: GID-TA11842 Expected publication date: TBC
Abaloparatide for treating idiopathic or hypogonadal osteoporosis in men [ID4059]
In development Reference number: GID-TA11036 Expected publication date: TBC
Awaiting development Reference number: GID-TA11716 Expected publication date: TBC
Awaiting development Reference number: GID-TA11836 Expected publication date: TBC
Awaiting development Reference number: GID-TA11639 Expected publication date: TBC
Navepegritide for treating achondroplasia in people 2 to 15 years [ID6538]
Awaiting development Reference number: GID-TA11699 Expected publication date: TBC
Obinutuzumab for treating serologically active extra-renal lupus [ID6670]
In development Reference number: GID-TA11886 Expected publication date: TBC
In development Reference number: GID-TA11809 Expected publication date: TBC
In development Reference number: GID-TA11052 Expected publication date: TBC
Norucholic acid for treating primary sclerosing cholangitis [ID6583]
In development Reference number: GID-TA11782 Expected publication date: TBC
In development Reference number: GID-TA11820 Expected publication date: TBC
Awaiting development Reference number: GID-TA11695 Expected publication date: TBC
Awaiting development Reference number: GID-TA11658 Expected publication date: TBC
Awaiting development Reference number: GID-TA11583 Expected publication date: TBC
by psychologists because this is considered important for achieving good patient outcomes. Taking into account the clinical and economic...
by psychologists because this is considered important for achieving good patient outcomes. Taking into account the clinical and economic...
Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) and chemotherapy for untreated metastatic non-small-cell lung cancer.
Neonatal infection: antibiotics for prevention and treatment (NG195)
This guideline covers preventing bacterial infection in healthy babies of up to and including 28 days corrected gestational age, treating pregnant women whose unborn baby is at risk of infection, and caring for babies of up to and including 28 days corrected gestational age with a suspected or confirmed bacterial infection. It aims to reduce delays in recognising and treating infection and prevent unnecessary use of antibiotics. The guideline does not cover viral infections.
This quality standard covers the provision of support for adults aged 18 or over who provide unpaid care for 1 or more people aged 16 or over with health and social care needs. It describes high-quality care in priority areas for improvement.
Icotrokinra for treating moderate to severe plaque psoriasis in people 12 years and over [ID6579]
In development Reference number: GID-TA11780 Expected publication date: TBC
Eneboparatide for treating chronic hypoparathyroidism [ID6532]
Awaiting development Reference number: GID-TA11688 Expected publication date: TBC
Awaiting development Reference number: GID-TA11660 Expected publication date: TBC
In development Reference number: GID-IPG10392 Expected publication date: TBC
Masitinib with riluzole for treating amyotrophic lateral sclerosis [ID6257]
In development Reference number: GID-TA11071 Expected publication date: TBC
Nipocalimab for treating generalised myasthenia gravis [ID6562]
Awaiting development Reference number: GID-TA11492 Expected publication date: TBC
Awaiting development Reference number: GID-TA11590 Expected publication date: TBC
We are listening to your views on this Technology appraisal guidance. Comments close 20 May 2026.
We are listening to your views on this Technology appraisal guidance. Comments close 21 May 2026.
Awaiting development Reference number: GID-TA11813 Expected publication date: TBC
In development Reference number: GID-TA11235 Expected publication date: TBC
Awaiting development Reference number: GID-TA11657 Expected publication date: 07 April 2027
Rebisufligene etisparvovec for treating mucopolysaccharidosis type IIIA [ID6540]
In development Reference number: GID-TA11701 Expected publication date: TBC
This guideline covers how to identify adults at high risk of type 2 diabetes. It aims to remind practitioners that age is no barrier to being at high risk of, or developing, the condition. It also aims to help them provide those at high risk with an effective and appropriate intensive lifestyle-change programme to prevent or delay the onset of type 2 diabetes. The recommendations in this guideline can be used alongside the NHS Health Check programme .
In development Reference number: GID-TA11765 Expected publication date: 24 March 2027
Awaiting development Reference number: GID-TA11723 Expected publication date: TBC
Awaiting development Reference number: GID-TA11626 Expected publication date: TBC
Awaiting development Reference number: GID-TA11535 Expected publication date: TBC
Awaiting development Reference number: GID-TA11162 Expected publication date: 28 July 2027
In development Reference number: GID-TA11804 Expected publication date: 08 October 2026
Awaiting development Reference number: GID-TA11724 Expected publication date: TBC
Awaiting development Reference number: GID-TA11499 Expected publication date: TBC